Reminding subscribers of an important chink in Big Pharma's armour

This is a massive weakness

Aug 29, 2022

∙ Paid

Investors take note—big pharma has no physical assets to develop drugs, nor the skills required

Investors hold the key to stopping big pharma antics There is one sure way to get the attention of big pharma—investors unhappy with the performance of their hard-earned cash injections (excuse the pun!). The previous post below should have given you a flavour of the risks and potholes that scatter the big pharma landscape…

3 years ago · 7 likes · Hedley Rees

This is a major chink in Big Pharma’s armour. When Wall Street and other investors get wind of it, if they haven't already, they will be running for the exits!

This is me explaining the chink to Megan Redshaw at TrialSite News:

Drug Development Expert Says Pharma’s 40-Year Love Affair with Outsourcing Must End

Also on YouTube:

INSIDE PHARMA

Reminding subscribers of an important chink in Big Pharma's armour

This is a massive weakness

Take a look at this:

This post is for paid subscribers